Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(β-L-malic acid) for drug delivery

Bioconjugate Chemistry

Volumn 17, Issue 2, 2006, Pages 317-326

  Lee, Bong Seop ^a,b   Fujita, Manabu ^b   Khazenzon, Natalya M ^b   Wawrowsky, Kolja A ^b   Wachsmann Hogiu, Sebastian ^b   Farkas, Daniel L ^b   Black, Keith L ^b,c   Ljubimova, Julia Y ^b,c   Holler, Eggehard ^a,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c Arrogene Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BRAIN; CELL CULTURE; CONTROLLED DRUG DELIVERY; COVALENT BONDS; MONOCLONAL ANTIBODIES; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; SULFUR COMPOUNDS; TARGETED DRUG DELIVERY; TUMORS;

ANTI-TRANSFERRIN RECEPTORS; ANTISENSE OLIGONUCLEOTIDES; BRAIN TUMORS; L-MALIC ACIDS; L-VALINE; LAMININ; MICROBIAL ORIGINS; SYNTHESISED; TARGETED DELIVERY; TISSUE TARGETING;

CHAINS;

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; BIOPOLYMER; CARBOXYL GROUP; FLUORESCENT DYE; LAMININ; LAMININ 8 ALPHA4; LAMININ 8 BETA1; MACROGOL; MONOCLONAL ANTIBODY; POLY(MALIC ACID); POLYCEFIN; POLYMER; SUCCINIMIDE DERIVATIVE; THIOESTER; THIOL DERIVATIVE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BIODEGRADABILITY; BRAIN TUMOR; CONJUGATE; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOCYTOSIS; ENDOSOME; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PROTEIN SYNTHESIS; TISSUE SPECIFICITY; VALIDATION PROCESS;

ANIMALIA;

EID: 33644962620     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0502457     Document Type: Article

References (51)

1. Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318.
2. Christie, R. J., and Grainger, D. W. (2003) Design strategies to improve soluble macromolecular delivery constructs. Adv. Drug Delivery Rev. 55, 421-437.
3. Duncan, R. (2003) The dawning era of polymer therapeutics. Nat Rev. 2, 347-360.
4. Zhang, Y., Zhu, C., and Pardridge, W. M. (2002) Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6, 67-72.
5. Vinogradov, S. V., Batrakova, E. V., and Kabanov, A. V. (2004). Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chem. 15, 50-60.
6. Mineura, K., and Kowada, M. (1996) Enhancement of 5-fluorouracil cytotoxicity by cisplatin in brain tumor cell lines. Cell Biol. Int. 20, 355-357.
7. Mologni, L., leCoutre, P., Nielsen, P. E., and Gambacorti-Passerini, C. (1998) Additive antisense effects of different PNAs on the in vitro translation of the PML/RARα gene. Nucleic Acids Res. 26, 1934-1938.
8. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392.
9. Muggia, F. M. (1999) Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5, 7-8.
10. Maeda, H. (2001) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 46, 169-185.
11. Maeda, H., Seymour, L. W., and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3, 351-362.
12. Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., and Ducan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31A, 766-770.
13. Pardridge, W. M. (1999) Vector-mediated drug delivery to the brain. Adv. Drug Delivery Rev. 36, 299-321.
14. Qian, Z. M., Li, H., Sun, H., and Ho, K. (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54, 561-587.
15. Baselga, J. (2001) The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer 37, S16-S22.
16. Leamon, C. P., and Reddy, J. A. (2004) Folate-targeted chemotherapy. Adv. Drug Delivery Rev. 56, 1127-1141.
17. Turk, M. J., Reddy, J. A., Chmielewski, J. A., and Low, P. S. (2002) Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. Biochim. Biophys. Acta 1559, 56-68.
18. Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G., and Wolff, J. A. (2003) Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconjugate Chem. 14, 51-57.
19. Philippova, O. E., Hourdet, D., Audebert, R., and Khokhlov, A. R. (1997) pH-responsive gels of hydrophobically modified poly-(acrylic acid). Macromolecules 30, 8278-8285.
20. Murthy, N., Robichaud, J. R., Tirrell, D. A., Stayton, P. S., and Hoffman, A. S. (1999) The design and synthesis of polymers for eukaryotic membrane disruption. J. Controlled Release 61, 137-143.
21. Lackey, C. A., Murthy, N., Press, O. W., Tirrell, D. A., Hoffman, A. S., and Stayton, P. S. (1999) Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates. Bioconjugate Chem. 10, 401-405.
22. Cheung, C. Y., Murthy, N., Stayton, P. S., and Hoffman, A. S. (2001) A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjugate Chem. 12, 906-910.
23. Murthy, N., Xu, M., Schuck, S., Kunisawa, J., Shastri, N., and Frechet, J. M. (2003) A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels. Proc. Natl. Acad. Sci. 100, 4995-5000.
24. Friedrich, B., Jung, K., Lein, M., Turk, I., Rudolph, B., Hampel, G., Schnorr, D., and Loening, S. A. (1999) Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. Eur. J. Cancer 35, 138-144.
25. Rodrigues, P. C. A., Scheuermann, K., Stockmar, C., Maier, G., Fiebig, H. H., Unger, C., Mülhaupt, R., and Kratza, F. (2003) Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 13, 355-360.
26. Saito, G., Swanson, J. A., and Lee, K. D. (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Delivery Rev. 55, 199-215.
27. Greenwald, R. B., Choe, Y. H., McGuire, J., and Conover, C. D. (2003) Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev. 55, 217-250.
28. Otsuka, H., Nagasaki, Y., and Kataoka, K. (2003) PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Delivery Rev. 55, 403-419.
29. Arpicco, S., Dosio, F., Bolognesi, A., Lubelli, C., Brusa, P., Stells, B., Ceruti, M., and Cattel, L. (2002) Novel Poly(ethylene glycol) derivatives for preparation of ribosome-inactivating protein conjugates. Bioconjugate Chem. 13, 757-765.
30. Maruyama, K., Takahashi, N., Toshiaki, T., Nagaike, K., and Iwatsuru, M. (1997) Immunoliposomes bearing poly(ethylene glycol)-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413, 177-180.
31. Kopecek, J., Kopecková, P., Minko, T., and Lu, Z. (2000) HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61-81.
32. Lu, Z. R., Shiah, J. G., Sakuma, S., Kopecková, P., and Kopecek, J. (2002) Design of novel bioconjugates for targeted drug delivery. J. Controlled Release 78, 165-173.
33. David, A., Kopecková, P., Minko, T., Rubinstein, A., and Kopecek, J. (2004) Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur. J. Cancer 40, 148-157.
34. Ulbrich, K., and Subr, V. (2004) Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Delivery Rev. 56, 1023-1050.
35. Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Samson, D. A., Greene, A. K., Corfas, G., and Folkman, J. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261.
36. Lee, B. S., Vert, M., and Holler, E. (2002) Water-soluble aliphatic polyesters: poly(malic acid)s. Biopolymers. Volume 3a: Polyesters 1 (Doi Y., and Steinbuechel A., Eds.) pp 75-103, Chapter 3, Wiley-VCH, New York.
37. Ljubimova, J. Y., Lakhter, A. J., Loksh, A., Yong, W. H., Riedinger; M. S., Miner, J. H., Sorokin, L. M., Ljubimov, A. V., and Black, K. L. (2001) Overexpression of α4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res. 61, 5601-5610.
38. Fujita, M., Khazenzon, N. M., Bose, S., Sekiguchi, K., Sasaki, T., Carter, W. G., Ljubimov, A. V., Black, K. L., and Ljubimova, J. Y. (2005) Overexpression of β1 chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res. 7, 411-421.
39. Khazenzon, N. M., Ljubimov, A. V., Lakhter, A. J., Fujita, M., Fujiwara, H., Sekiguchi, K., Sorokin, L. M., Petäjäemi, N., Virtanen, I., Black, K. L., and Ljubimova, J. Y. (2003) Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol. Cancer Ther. 2, 985-994.
40. Summerton, J., and Weller, D. (1997) Morpholino antisense oligomers: Design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
41. Jefferies, W. A., Brandon, M. R., Williams, A. F., and Hunt, V. (1985) Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 54, 333.
42. 125I-transferrin through the rat blood-brain barrier, Brain Res. 683, 164-171.
43. Thorstensen, K., and Romslo, I. (1993) The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand. J. Clin. Lab Invest. 53, 113-120.
44. Singh, M. (1999) Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5, 443-451.
45. Broadwell, R. D., Baker-Cairns, B. J., Frieden, P. M., Oliver, C., and Villegas, J. C. (1996) Transcytosis of protein through the mammalian cerebral epithelium and endothelium III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142, 47-65.
46. Carlsson, J., Drevin, H., and Axen, R. (1978) Protein thiolation and reversible protein-protein conjugation. Biochem. J. 173, 723-737.
47. Arora, V., Knapp, D. C., Smith, B. L., Stadtfield, M. L., Stein, D. A., Reddy, M. T., Weller, D. D., and Iversen, P. L. (2000) c-Myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J. Pharmacol. Exp. Ther. 292, 921-928.
48. 1 integrins. J. Biol. Chem. 276, 17550-17558.
49. Duncan, R. (2003) The dawning era of polymer therapeutics. Nat. Rev. Drug. Discovery 2, 347-360.
50. Nori, A., and Kopecek, J. (2005) Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Delivery Rev. 57, 609-636.
51. Duncan, R., Vicent, M. J., Greco, F., and Nicholson, R. I. (2005) Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer 12 Suppl. 1, S189-199.